Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A pharmaceutical preparation capable of lowering blood sugar

A pharmaceutical preparation and blood sugar technology, applied in the field of pharmaceutical preparations, can solve the problems of cumbersome use and multiple injections, and achieve the effects of stimulating insulin secretion, facilitating clinical promotion and use, and fewer types of drug compatibility

Inactive Publication Date: 2011-12-28
SHANXI MEDICAL UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the problem of multiple injections of various drugs, cumbersome use and great pain to patients when clinically lowering blood sugar, the present invention provides a stable drug preparation that can lower blood sugar with gAd and GLP-1 as main components , through the reasonable compatibility of gAd and GLP-1, the clinical therapeutic effect is strengthened

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical preparation capable of lowering blood sugar
  • A pharmaceutical preparation capable of lowering blood sugar
  • A pharmaceutical preparation capable of lowering blood sugar

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1: the pharmaceutical preparation that can lower blood sugar, comprises the gAd that concentration is 200ng / mL, 13 g / mL GLP-1, 0.01mmol / L phosphate buffer and 0.03mol / L EDTA, the rest is water, and the pH is 7.4.

[0020] Preparation method: 1), preparation of medicinal buffer: weigh 8g NaCl, 0.2g KCl, 1.44g Na 2 HPO 4 , 0.24g KH 2 PO 4 , 12g EDTA·2Na was dissolved in 800ml distilled water, and finally added distilled water to make the volume to 800mL to obtain 0.01mmol / L phosphate buffer, stabilizer 0.03mol / L EDTA mixed solution, which is the medicinal buffer of the present invention solution (because the purpose of this example is to prepare 1000mL drug liquid injection, it is necessary to reserve a certain volume for the addition of gAd and GLP-1).

[0021] 2) Using the medicinal buffer solution obtained in step 1), prepare gAd and GLP-1 proteins (or their aqueous solutions) into concentrated solutions using conventional operating methods, and then ro...

Embodiment 2

[0024] Embodiment 2: the pharmaceutical preparation that can lower blood sugar, comprises the gAd that concentration is 800ng / mL, 3 g / mL GLP-1, phosphate buffer 0.02mmol / L and benzyl alcohol 0.5% (V / V), the rest is water, pH 7.4.

[0025] Referring to Example 1 for the preparation method, those skilled in the art can easily know that the pharmaceutical buffer is phosphate buffer, and the stabilizer is benzyl alcohol.

Embodiment 3

[0026] Embodiment 3: the pharmaceutical preparation that can lower blood sugar, comprises the gAd that concentration is 2000ng / mL, 15 GLP-1 at g / mL, mannitol buffer 10% (V / V) and m-cresol 1.0% (V / V), the rest is water, pH 7.4.

[0027] Referring to Example 1 for the preparation method, those skilled in the art can easily know that the medicinal buffer is mannitol buffer, and the stabilizer is m-cresol.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a pharmaceutical preparation capable of lowering blood sugar, which solves the problems of multiple injections of various drugs, cumbersome use, and great pain to patients during clinical lowering of blood sugar. The drug can lower blood sugar The preparation is characterized in that it uses adiponectin globular domain (gAd) and glucagon-like peptide-1 (GLP-1) as main components, including gAd at a concentration of 200ng / ml to 2000ng / ml, 3μg / ml ml to 15 μg / ml GLP-1, pharmaceutical buffer, stabilizer, and water, pH 7.4. The characteristics of the present invention are: (1) a novel hypoglycemic drug that can not only alleviate the IR state of body tissues, but also stimulate the secretion of insulin in the body; (2) have fewer types of drug compatibility; (3) facilitate clinical popularization and use.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a pharmaceutical preparation that can lower blood sugar, specifically a kind of adiponectin globular domain (gAd) and glucagon-like peptide-1 (GLP-1) as the main Ingredients of pharmaceutical preparations. Background technique [0002] Insulin resistance (IR) is the common pathophysiological basis of many metabolic diseases such as Type 2 diabetes mellitus (T2DM), coronary heart disease, hypertension, dyslipidemia, obesity (Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey [J]. JAMA. 2000, 283(18):2404-2410.). Therefore, how to improve IR has become a practical problem to be solved urgently in clinical medicine. IR refers to the decreased sensitivity of the target organ of insulin action to insulin action, that is, a metabolic s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/26A61K38/22A61P3/10
Inventor 王彦陈显久杨静黄敏廉如陈思思高婷婷
Owner SHANXI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products